Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
12600 participants
OBSERVATIONAL
2022-09-30
2022-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safe Pregnancy by Infectious Disease Control
NCT00489619
Prevalence and Impact of COVID-19 on Maternal and Infant Health in African Populations
NCT05303168
ANC COVID-19 Surveillance
NCT07021807
Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID-19.
NCT04322279
Evaluation of the New Variant 501Y.V2 of COVID-19
NCT04906850
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The research will combine retrospective and prospective approaches to determine the evolutionary dynamics of the virus since the start of the pandemic. It is planned to sequence the entire Spike protein gene for 1550 viruses and make 300 entire genomes. This work will be supplemented by antibody seroneutralization and respiratory transcriptomics tests, in order to estimate the immuno-virological response of the COVID-19 disease associated with the identified SARS-CoV-2 variants.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Retrospective
12000 participants positive for SARS-COV-2
RT PCR
Characterize the different molecular variants of SARS-CoV-2, determine the escape potential of the new variants from neutralization by monoclonal antibodies and currently available vaccines and characterization of the mRNAs expressed in infected persons
Prospective
600 participants positive for SARS-COV-2
RT PCR
Characterize the different molecular variants of SARS-CoV-2, determine the escape potential of the new variants from neutralization by monoclonal antibodies and currently available vaccines and characterization of the mRNAs expressed in infected persons
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RT PCR
Characterize the different molecular variants of SARS-CoV-2, determine the escape potential of the new variants from neutralization by monoclonal antibodies and currently available vaccines and characterization of the mRNAs expressed in infected persons
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presenting for a SARS-COV-2 diagnosis, whether symptomatic or not
* Not objecting to participating in the research
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut de Recherche pour le Developpement
OTHER_GOV
Institut National de la Santé Et de la Recherche Médicale, France
OTHER_GOV
ANRS, Emerging Infectious Diseases
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre de Référence pour les pathogènes émergents et réémergent
Bobo-Dioulasso, , Burkina Faso
Centre Hospitalier Universitaire la Référence Nationale (CHU-RN)
N'Djamena, , Chad
CIRBA
Abidjan, , Côte d’Ivoire
Unité Mixte de Recherche CIRMF-SSM
Libreville, , Gabon
SEREFO
Bamako, , Mali
Laboratoire National de Santé Publique Brazzaville
Brazzaville, , Republic of the Congo
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANRS 0136s
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.